Peter Attia· MD
and he said I think that's what we're seeing now with the glp1 agonists as well as some other drugs
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and he said I think that's what we're seeing now with the glp1 agonists as well as some other drugs
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
I don't have a moral issue with the remarkable success of the drug class that is now probably going to be the first thing that bends The Arc of this I don't know when the next check-in will be the next en haanes check-in but it it seems now it's annual yeah so it seems likely that very soon if not already we're going to see for the first time in five decades obesity rates going down